First treatment strategies in the 2 years following lung cancer diagnosis. ESCAP-2011-CPHG, a real-life study carried out in French general hospitals
Copyright © 2017 SPLF. Published by Elsevier Masson SAS. All rights reserved..
INTRODUCTION: The objective of the ESCAP-2011-CPHG cohort study was to perform a real-life analysis of therapeutic strategies used during the first 2years of follow-up after a diagnosis of primary lung cancer. This paper presents the study and its first results in non-small-cell lung cancer (NSCLC).
METHODS: Pulmonologists in the respiratory disease departments of 53 general hospitals consecutively included all patients aged 18years and over with lung cancer newly diagnosed in 2010.
RESULTS: Of the 3943 patients included, 3418 (mean age: 65.4 years; male: 76%; never smokers: 12%) had NSCLC (adenocarcinoma: 53%; stages 0-II, IIIA, IIIB and IV: 18, 14, 9 and 59%, respectively). Mean follow-up was 13.2 (SD: 10.1) months; mean number of strategies implemented was 2 (SD: 1.3). Overall, 62% of patients had chemotherapy in the first strategy (74% in the second strategy); the rate of chemotherapy alone increased from 6 to 56% with cancer stage.
CONCLUSIONS: ESCAP-2011-CPHG opens the way to many possible analyses of the therapeutic strategies currently implemented in French hospitals, comparing strategies, survival or patient characteristics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Revue des maladies respiratoires - 34(2017), 9 vom: 01. Nov., Seite 991-999 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Stratégies thérapeutiques les 2 premières années après un diagnostic de cancer du poumon. ESCAP-2011-CPHG, étude en situation réelle réalisée dans les hôpitaux généraux français |
|---|
| Beteiligte Personen: |
Grivaux, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Étude épidémiologique |
|---|
| Anmerkungen: |
Date Completed 24.10.2018 Date Revised 24.10.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rmr.2017.10.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM277782643 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM277782643 | ||
| 003 | DE-627 | ||
| 005 | 20231225015046.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.rmr.2017.10.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0925.xml |
| 035 | |a (DE-627)NLM277782643 | ||
| 035 | |a (NLM)29111174 | ||
| 035 | |a (PII)S0761-8425(17)30268-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Grivaux, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a First treatment strategies in the 2 years following lung cancer diagnosis. ESCAP-2011-CPHG, a real-life study carried out in French general hospitals |
| 246 | 3 | 3 | |a Stratégies thérapeutiques les 2 premières années après un diagnostic de cancer du poumon. ESCAP-2011-CPHG, étude en situation réelle réalisée dans les hôpitaux généraux français |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.10.2018 | ||
| 500 | |a Date Revised 24.10.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 SPLF. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a INTRODUCTION: The objective of the ESCAP-2011-CPHG cohort study was to perform a real-life analysis of therapeutic strategies used during the first 2years of follow-up after a diagnosis of primary lung cancer. This paper presents the study and its first results in non-small-cell lung cancer (NSCLC) | ||
| 520 | |a METHODS: Pulmonologists in the respiratory disease departments of 53 general hospitals consecutively included all patients aged 18years and over with lung cancer newly diagnosed in 2010 | ||
| 520 | |a RESULTS: Of the 3943 patients included, 3418 (mean age: 65.4 years; male: 76%; never smokers: 12%) had NSCLC (adenocarcinoma: 53%; stages 0-II, IIIA, IIIB and IV: 18, 14, 9 and 59%, respectively). Mean follow-up was 13.2 (SD: 10.1) months; mean number of strategies implemented was 2 (SD: 1.3). Overall, 62% of patients had chemotherapy in the first strategy (74% in the second strategy); the rate of chemotherapy alone increased from 6 to 56% with cancer stage | ||
| 520 | |a CONCLUSIONS: ESCAP-2011-CPHG opens the way to many possible analyses of the therapeutic strategies currently implemented in French hospitals, comparing strategies, survival or patient characteristics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cancer bronchique primitif | |
| 650 | 4 | |a Epidemiologic study | |
| 650 | 4 | |a France | |
| 650 | 4 | |a Primary lung cancer | |
| 650 | 4 | |a Stade | |
| 650 | 4 | |a Stage | |
| 650 | 4 | |a Traitement | |
| 650 | 4 | |a Treatment | |
| 650 | 4 | |a Étude épidémiologique | |
| 700 | 1 | |a Goupil, F |e verfasserin |4 aut | |
| 700 | 1 | |a Asselain, B |e verfasserin |4 aut | |
| 700 | 1 | |a Blanchon, F |e verfasserin |4 aut | |
| 700 | 1 | |a Collon, T |e verfasserin |4 aut | |
| 700 | 1 | |a Coëtmeur, D |e verfasserin |4 aut | |
| 700 | 1 | |a Dayen, C |e verfasserin |4 aut | |
| 700 | 1 | |a Locher, C |e verfasserin |4 aut | |
| 700 | 1 | |a Molinier, O |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, F |e verfasserin |4 aut | |
| 700 | 1 | |a Debieuvre, D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue des maladies respiratoires |d 1988 |g 34(2017), 9 vom: 01. Nov., Seite 991-999 |w (DE-627)NLM012622443 |x 1776-2588 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2017 |g number:9 |g day:01 |g month:11 |g pages:991-999 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmr.2017.10.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2017 |e 9 |b 01 |c 11 |h 991-999 | ||